Clinical trials: Cancer, Bladder
Urothelial Carcinoma, Urothelial Carcinoma Bladder
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT03606174
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 36 sites in United States
- Volunteers
- 260 people
- Sponsor
- Mirati Therapeutics Inc.
Non-Muscle Invasive Bladder Cancer, NMIBC
Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)
The SCORE-NMIBC study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with non-muscle Invasive Bladder Cancer (NMIBC).
- Conditions
- Non-Muscle Invasive Bladder Cancer, NMIBC, High-risk Non-Muscle Invasive Bladder Cancer
- Trial name
- SCORE-NMIBC (NCT07763197)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Natera, Inc.
Bladder Cancer
Study of Weekly Radiotherapy for Bladder Cancer
Background Localised muscle invasive bladder cancer (MIBC) is life-threatening and can cause significant symptoms. Around 50% of patients with MIBC who are referred for radiotherapy are unfit for standard radical treatment…
- Trial name
- HYBRID (NCT01810757)
- Testing
- Standard planning radiotherapy, Adaptive planning radiotherapy
- Where
- 11 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma Ureter
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
There is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one…
- Trial name
- NCT04865939
- Testing
- sterile water irrigation, Gemcitabine
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- University of Texas Southwestern Medical Center
Low-grade NMIBC, FGFR Gene Amplification
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
- Conditions
- Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration
- Trial name
- SURF302 (NCT06995677)
- Testing
- TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg
- Where
- 48 sites in United States, Australia and 2 more
- Volunteers
- 90 people
- Sponsor
- Tyra Biosciences, Inc
Bladder Cancer
The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial
The study will be a prospective two arms diagnostic phase II single-center trial. Patients referred for diagnosis and treatment with diagnosis of bladder cancer, age > 18 years, ECOG performance status < 2, ability to undergo an…
- Trial name
- FUTURE (NCT07257718)
- Testing
- FAPI PET/CT and liquid biopsy in patients eligible for radical cystectomy, FAPI PET/CT and liquid biopsy in patients eligible for conservative treatment
- Volunteers
- 262 people
- Sponsor
- Chiti Arturo
Non-muscle Invasive Bladder Cancer
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC).
- Trial name
- NCT06126796
- Testing
- CxBladder Monitor, Cystoscopy
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Mayo Clinic
Bladder Cancer
Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
Patients with non-invasive bladder cancer are often treated with intravesical therapy in order to prevent the recurrence of bladder cancer.
- Trial name
- NCT01489813
- Testing
- Genistein, Sugar pill
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Circulatory Function, Laparoscopic Radical Cystectomy for Bladder Cancer
Circulatory Function in Laparoscopic Radical Cystectomy for Bladder Cancer
To optimize the perioperative management of patients undergoing laparoscopic radical cystectomy(LPC) for bladder cancer through observation of perioperative changes of Brain Natriuretic Peptide(BNP), stroke volume variation(SVV)…
- Trial name
- NCT03892031
- Where
- China
- Volunteers
- 186 people
- Sponsor
- RenJi Hospital
Pain, Postoperative
Perioperative Analgesic Efficiency of Quadratus Lumborum Block vs Epidural in Radical Cystectomy
This study is performed to measure the perioperative analgesic efficiency of bilateral quadratus lumborum block versus epidural analgesia in bladder cancer patients undergoing radical cystectomy
- Trial name
- NCT04133051
- Testing
- Quadratus Lumborum Block Using Bupivacaine 0.2%, Epidural Analgesia Using Bupivacaine 0.25%
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute, Egypt
Non Muscle Invasive Bladder Cancer
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.
- Trial name
- NCT05981131
- Testing
- N803 plus Bacillus Calmette-Guerin (BCG)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ImmunityBio, Inc.
Urinary Bladder Cancer
Intravesical Gem/Doce in Patients With NMIBC
Intravesical immunotherapy or chemotherapy for non-muscle invasive bladder cancer (NMIBC) is a well-established treatment for preventing or delaying tumor recurrence after tumor resection.
- Trial name
- NCT05644041
- Testing
- gemcitabine + docetaxel
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Arizona
Muscle Invasive Bladder Cancer (MIBC)
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
This is a multicenter, open-label, prospective, single-arm, phase II study designed to evaluate the efficacy and safety of neoadjuvant zanidatamab combined with tislelizumab and chemotherapy, followed by selective bladder…
- Trial name
- HARBOR (NCT07296705)
- Testing
- Zanidatamab, Tislelizumab, Cisplatin
- Where
- 12 sites in China
- Volunteers
- 25 people
- Sponsor
- Fujian Medical University Union Hospital
Urologic Neoplasms, Metastatic Bladder Cancer
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled…
- Conditions
- Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms
- Trial name
- NCT01454089
- Testing
- OGX-427 600 mg, OGX-427 1000 mg, Gemcitabine
- Where
- 55 sites in United States, Canada and 5 more
- Volunteers
- 183 people
- Sponsor
- Achieve Life Sciences
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
R115777 in Treating Patients With Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have advanced bladder…
- Trial name
- NCT00006376
- Testing
- chemotherapy, tipifarnib
- Where
- 2 sites in United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Muscle Invasive Bladder Cancer
Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer
The investigators hypothesize that low energy shock wave therapy (LESW) might induce damage to the tumor tissues of non-muscle invasive bladder cancer (NMIBC), so they could be ablated and detached from the surface.
- Trial name
- NCT04644835
- Testing
- Low Energy Shock Wave Treatment
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Mansoura University
Prostate Cancer, Bladder Cancer
Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy
Laparoscopic and minimally-invasive robotic access has transformed the delivery of urological surgery. While associated with numerous desirable outcomes including shorter post-operative stay and faster return to preoperative…
- Conditions
- Prostate Cancer, Bladder Cancer, Surgery, Renal Impairment
- Trial name
- NCT06408597
- Testing
- Nitroglycerin Infusion, Mannitol Infusion, Fluid Regimen
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Nazmy Edward Seif
Bladder Cancer
Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer
RATIONALE: New diagnostic procedures such as microsatellite analysis of sediment in the urine may improve the ability to detect bladder cancer without invasive procedures.
- Trial name
- NCT00095589
- Testing
- loss of heterozygosity analysis, microarray analysis, microsatellite instability analysis
- Where
- 13 sites in United States, Canada
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HER2-positive Breast Cancer, HER2 Low
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.
- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985
- Trial name
- NCT04602117
- Testing
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- QuantumLeap Healthcare Collaborative
Muscle-Invasive Bladder Cancer (MIBC)
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
The purpose of this Phase II, open-label, multicenter, randomized controlled study is to evaluate the efficacy and safety of Enfortumab Vedotin in combination with Toripalimab compared to Gemcitabine plus Cisplatin.
- Trial name
- NCT07647289
- Testing
- enfortumab vedotin (EV), Toripalimab, Gemcitabine (Chemotherapy)
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Peking University Third Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.